eGFR decline in patients with IgAN treated with Nefecon or placebo: Results from the 2-year NefIgArd Phase 3 trial

17:15–17:24, 02 November 2023
Philadelphia, Pennsylvania, United States

Authors: Richard Lafayette¹, Jens Kristensen², Andrew Stone³, Jürgen Floege⁴, Vladimir Tesar⁵, Hernán Trimarchi⁶, Hong Zhang⁷, Necmi Eren⁸, Alexander Paliege⁹, Heather Reich¹⁰, Brad Rovin¹¹, Jonathan Barratt¹²

Affiliations: ¹Division of Nephrology, Department of Medicine, Stanford University, Stanford, CA, USA; ²Calliditas Therapeutics AB, Stockholm, Sweden; ³Stone Biostatistics Ltd., Crewe, UK; ⁴Department of Nephrology and Clinical Immunology, Rheinisch Westfälische Technische Hochschule Aachen University Hospital, Aachen, Germany; ⁵Department of Nephrology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic; ⁶Nephrology Service, Hospital Británico de Buenos Aires, Buenos Aires, Argentina; ⁷Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China; ⁸Department of Nephrology, Kocaeli University, Kocaeli, Turkey; ⁹Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; ¹⁰Division of Nephrology, University Health Network, Department of Medicine, University of Toronto, Toronto, ON, Canada; ¹¹Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH, USA; ¹²College of Medicine Biological Sciences and Psychology, University of Leicester, Leicester, UK

Date of preparation: October 2023
Disclosures: Richard Lafayette

• Received institutional grants and consultation from Beigene, Calliditas Therapeutics, ChemoCentryx, Novartis, Omeros, Otsuka, Roche, Travere Therapeutics, Vera Therapeutics, and Visterra

• Served on Data Safety Monitoring Boards for Cara Therapeutics, AMGEN
Calliditas Therapeutics

Introduction

• Nefecon is a novel, oral, targeted-release capsule formulation of budesonide, specifically designed to treat IgAN by inhibiting IgA formation in the Peyer’s-patch–rich distal ileum

• Results from the full 2-year Phase 3 NefIgArd study evidenced an eGFR treatment benefit vs placebo and durable reduction in proteinuria after 9 months of treatment and 15 months of observational follow-up
  – Time-weighted average of eGFR over 2 years showed a statistically significant treatment benefit in favor of Nefecon 16 mg/day (difference 5.05 mL/min/1.73 m² [95% CI 3.24, 7.38]; p<0.0001) versus placebo; eGFR treatment benefit was maintained over the 15-month follow-up
  – A significant 41% reduction in time-averaged UPCR from 12 to 24 months was seen in the Nefecon group compared with placebo (95% CI 32, 49; p<0.0001)

• Here, we present data from the complete NefIgArd study for the composite endpoint of time to confirmed 30% eGFR reduction or kidney failure

Cl, confidence interval; eGFR, estimated glomerular filtration rate; IgA, immunoglobulin A; IgAN, immunoglobulin A nephropathy; UPCR, urine protein-creatinine ratio.
Methods

**NefIgArd: A Phase 3, two-part, randomized, double-blind, placebo-controlled trial**

**Aim of the analysis:** To assess the effect of Nefecon 16 mg/day on eGFR decline in patients with IgAN over the 9-month treatment period and 15-month observational follow-up period of the Phase 3 NefIgArd trial

**Key inclusion criteria:**
- ≥18 years old with biopsy-confirmed primary IgAN
- eGFR 35-90 mL/min/1.73 m²
- UPCR ≥0.8 g/g or proteinuria ≥1 g/24h, despite optimized RAS inhibition

**Key exclusion criteria:**
- Secondary form of IgAN or non-IgAN glomerulonephritis
- Kidney transplantation
- Systemic diseases that may cause mesangial IgA deposition
- Poorly controlled BP (≥140/90 mmHg)
- Poorly controlled T1D or T2D

**Primary efficacy endpoint:** Time-weighted average of eGFR over 2 years

**Secondary efficacy endpoint:** Composite endpoint of time from randomization to confirmed 30% reduction in eGFR* or confirmed kidney failure (dialysis for ≥1 month, kidney transplantation, sustained [≥1 month] eGFR <15 mL/min/1.73 m², or kidney-related death)

*Confirmed by two values over 24 weeks

BP, blood pressure; eGFR, estimated glomerular filtration rate; IgA, immunoglobulin A; IgAN, immunoglobulin A nephropathy; RAS, renin–angiotensin system; T1D, type 1 diabetes; T2D, type 2 diabetes; UPCR, urine protein-creatinine ratio.

eGFR at 9 and 24 months

Sustained eGFR effect observed at 24 months\(^1,2\)

9 months of treatment with Nefecon (16 mg/day) in 364 patients resulted in approximately **50% less deterioration of kidney function** versus placebo at 24 months.

### Efficacy findings\(^1,2\)

- **Time-weighted average of eGFR over 2 years:**
  - Nefecon: -2.47 mL/min per 1.73 m\(^2\)
  - Placebo: -7.52 mL/min per 1.73 m\(^2\)
  - Difference: 5.05 mL/min per 1.73 m\(^2\) (95% CI 3.24, 7.38, p<0.0001)

- **After 9 months:**
  - eGFR increase in Nefecon-treated patients: 0.66 mL/min/1.73m\(^2\)
  - eGFR decrease in placebo-treated patients: 4.56 mL/min/1.73m\(^2\)

- **After 24 months:**
  - eGFR decrease in Nefecon-treated patients: 6.11 mL/min/1.73m\(^2\)
  - eGFR decrease in placebo-treated patients: 12.00 mL/min/1.73m\(^2\)

---


Secondary endpoint: UPCR at 9 and 24 months

A 30% reduction in UPCR with Nefecon compared with placebo was observed after the 9-month treatment period, which was sustained for up to 2 years

*Baseline is defined as the geometric mean of the two consecutive measurements prior to randomization. Percentage change in UPCR from baseline = (geometric LS mean of ratio of postbaseline value/baseline value for each treatment arm - 1) x 100.

CI, confidence interval; LS, least squares; UPCR, urine protein-creatinine ratio.

Secondary endpoint: Time to 30% reduction in eGFR or kidney failure

Time to composite endpoint of confirmed 30% eGFR reduction from baseline or kidney failure*

- Nefecon 16 mg/day versus placebo: HR 0.45 (95% CI 0.26, 0.75), p=0.0014 (1-sided)†

### HR (95% CI)

<table>
<thead>
<tr>
<th>Rescue medication counted as event</th>
<th>0.51 (0.33, 0.79)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regardless of rescue medication‡</td>
<td>0.44 (0.27, 0.71)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients who experienced an event, % (n/N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nefecon</td>
</tr>
<tr>
<td>Placebo</td>
</tr>
</tbody>
</table>

The time to a **confirmed 30% eGFR reduction or kidney failure event** was **significantly delayed** with Nefecon vs placebo

---

*A 30% reduction in eGFR was confirmed by two values over ≥4 weeks. To prevent informative censoring, death from a renal-related event, patients who experienced dialysis for at least 1 month, kidney transplantation or kidney failure (defined as a sustained eGFR <15 mL/min/1.73 m² prior to a 30% reduction) were included as having had a clinical event occurring at that time.

†In an IPCW analysis, patients who received rescue medication or other prohibited immunosuppressive medications were censored at the time of their last eGFR measurement before receiving the medication. Post hoc analysis using a standard Cox model. CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IPCW, inverse probability of censoring weights.
Secondary endpoint: Time to 30% reduction in eGFR or kidney failure by UPCR subgroup

Post hoc analysis: Time to confirmed 30% eGFR reduction or kidney failure in the absence of rescue medication stratified by UPCR subgroup*

<table>
<thead>
<tr>
<th></th>
<th>Nefecon n/N (%)</th>
<th>Placebo n/N (%)</th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>21/182 (12)</td>
<td>39/182 (21)</td>
<td>0.45 (0.26, 0.75)</td>
</tr>
<tr>
<td>UPCR &lt;1.5 g/g</td>
<td>9/117 (8)</td>
<td>16/118 (14)</td>
<td>0.51 (0.21, 1.12)</td>
</tr>
<tr>
<td>UPCR ≥1.5 g/g</td>
<td>12/65 (18)</td>
<td>23/64 (36)</td>
<td>0.42 (0.21, 0.83)</td>
</tr>
</tbody>
</table>

Nefecon treatment effect on risk of 30% reduction in eGFR or kidney failure was consistent irrespective of baseline UPCR category

*In an IPCW analysis, patients who received rescue medication or other prohibited immunosuppressive medications were censored at the time of their last eGFR measurement before receiving the medication. A 30% reduction in eGFR was confirmed by two values over ≥4 weeks, and kidney failure was defined as dialysis for ≥1 month, kidney transplantation, sustained (≥1 month) eGFR <15 mL/min/1.73 m², or kidney-related death.
CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; IPCW, inverse probability of censoring weights; UPCR, urine protein-creatinine ratio.
Summary of TEAEs during treatment period*

**TEAEs (≥5% in the Nefecon 16-mg/day arm)**

<table>
<thead>
<tr>
<th>Adverse event, N (%)</th>
<th>Nefecon 16 mg (N=182)</th>
<th>Placebo (N=182)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peripheral edema†,‡</td>
<td>31 (17)</td>
<td>7 (4)</td>
</tr>
<tr>
<td>Hypertension§</td>
<td>22 (12)</td>
<td>6 (3)</td>
</tr>
<tr>
<td>Muscle spasms</td>
<td>22 (12)</td>
<td>7 (4)</td>
</tr>
<tr>
<td>Acne</td>
<td>20 (11)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Headache</td>
<td>19 (10)</td>
<td>14 (8)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>17 (9)</td>
<td>19 (10)</td>
</tr>
<tr>
<td>Face edema‡</td>
<td>14 (8)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>13 (7)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>12 (7)</td>
<td>4 (2)</td>
</tr>
<tr>
<td>URTI</td>
<td>10 (5)</td>
<td>10 (5)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>10 (5)</td>
<td>7 (4)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>10 (5)</td>
<td>7 (4)</td>
</tr>
<tr>
<td>Rash</td>
<td>10 (5)</td>
<td>7 (4)</td>
</tr>
<tr>
<td>Increase in weight</td>
<td>10 (5)</td>
<td>5 (3)</td>
</tr>
</tbody>
</table>

*Includes only adverse events that started during treatment up to 14 days after the last treatment dose (i.e., the last dose the patient received including the tapering period, regardless of treatment duration). Five patients (n=2 in the Nefecon group and n=3 in the placebo group) did not start study treatment.

†One patient receiving Nefecon experienced a TEAE graded as severe. ‡One patient receiving Nefecon experienced a TEAE classed as serious. §Two patients receiving Nefecon experienced a TEAE classed as serious.

During the 9-month treatment period, **Nefecon 16 mg/day was well tolerated**, with a safety profile as expected for a locally acting oral budesonide product.  

---

Conclusions

• The time from randomization to confirmed 30% reduction in eGFR or kidney failure was significantly delayed with Nefecon vs placebo
  — HR 0.45 (95% CI 0.26, 0.75) p=0.0014 (1-sided)

• The Nefecon vs placebo treatment effect was similar irrespective of handling of rescue medication
  — Rescue medication counted as an event: HR 0.51 (95% CI 0.33, 0.79)
  — Regardless of rescue medication: HR 0.44 (95% CI 0.27, 0.71)

• The treatment effect of Nefecon vs placebo was consistent irrespective of baseline UPCR category
  — UPCR <1.5 g/g: HR 0.51 (95% CI 0.21, 1.12)
  — UPCR ≥1.5 g/g: HR 0.42 (95% CI 0.21, 0.83)

• These findings strongly indicate preserved kidney function with Nefecon and provide support for Nefecon as a disease-modifying therapy in patients with IgAN

---
eGFR, estimated glomerular filtration rate; HR, hazard ratio; IgAN, immunoglobulin A nephropathy; UPCR, urine protein-creatinine ratio.
Acknowledgments

• We thank the investigators involved in the conduct of the trial, and the patients and their families for their participation. The study was funded by Calliditas Therapeutics. Medical writing support was provided by Roshni Patel and Matej Broadbent of Chameleon Communications International, UK, with financial support from Calliditas Therapeutics and in accordance with the 2022 Good Publication Practice guidelines (https://www.ismpp.org/gpp-2022).